Skip to main content

Table 1 Distribution of patients according to demographic features, clinico-laboratory data, O2 requirements, and therapy

From: COVID-19-induced vascular angiopathy: CTPA signs in critically ill patients other than acute pulmonary embolism and high-lung opacity scores

Demographic features (N-%) Clinical data (N-%) Laboratory profile (N-%) O2 status and needs (N-%)
• Age • Duration (time interval) • D-dimer • O2 saturation at room air
- <45 18 (24.7%) - 2nd week 20 (27.4%) - Normal 6 (8.2%) - 80%: < 93% 55 (75.3%)
- ≥45 55 (75.3%) - 3rd week 22 (30.1%) - High without PE 43 (58.9%) - < 80% 18 (24.7%)
- Mean ± SD 53.3 ± 13.5 - 4th week 28 (38.4%) - High with PE 24 (32.9%) • O2 requirements:
- (Min.–Max.) (18–88) - 2nd month 3 (4.1%) - Mean 1574.1 - High flow nasal O2: 58 (79.5%)
     - SD 1392.2 - Mechanical ventilation: 15 (21.5%)
• Sex • Symptoms • CRP   
- Male 53 (72.6%) - Dyspnea 63 (86.3%) - Normal 7 (9.6%)   
- Female 20 (27.4%) - Fever 61 (83.6%) - High 66 (90.4%)   
   - Cough 54 (74%) - Mean 7.8   
   - Chest pain 8 (11%) - SD 7.3   
   - GIT-related 16 (21.9%) • Lymphocytic count   
   • Lung co-morbidities - Normal 3 (4.1%)   
   - Asthma 4 (66.7%) - Low 70 (95.9%)   
   - Emphysema 2 (33.3%)     
   • General co-morbidities    
   - Hypertension 32 (43.8%)     
   - Diabetes 25 (34.2%)     
   - Lymphoma 1 (1.4%)